Latest Industry Insights

In this opinion piece, Philipp Koellinger explores the changes required to level the playing field and accelerate both scientific and technological progress.

In this interview, Technology Networks spoke with Dr. Laura Lyon, product manager of cell culture technologies at Sartorius, to explore the critical role of cytokines and growth factors in in vitro experiments.

Dr. Emanuela Costigliola discusses recent advances in preclinical drug development and the significance of physiologically relevant models in predicting human responses.

In an interview with Technology Networks, Dr. Frederic Cedrone, vice president of corporate innovation at Catalent, discussed the challenges faced and solutions found by companies developing iPSC-derived cell therapies.

In this interview, Technology Networks spoke with Dr. Jingwen Ding, senior applications scientist at SCIEX, to understand how charge variant analysis and advanced technologies can enhance biopharmaceutical workflows.

Technology Networks asked a selection of start-up companies at ELRIG Drug Discovery how their technology addresses key limitations in traditional disease models.

In this interview, Dr. Mitzy Rios de Anda sheds light on the potential of human iPSC-derived astrocytes, discussing how these cells are reshaping our understanding of the brain, neurological diseases and therapeutic development.

Technology Networks spoke with Nicola Alderson, COO at Anthony Nolan, to discuss some of the current stem cell supply challenges and learn more about how donor registries can help overcome stem cell supply chain issues.

In this interview, Xiaobo Wang discusses some of the NovoCyte Opteon’s advanced spectral capabilities and how they help to address existing challenges in flow cytometry.

In this interview, we spoke to Jason Koth, product management lead at Scale Biosciences, to learn more about their new ScalePlex technology for leveraging and overcoming current limitations within single-cell genomics.